Hologic Inc. logo

Hologic Inc. (HOLX)

Market Closed
10 Jun, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
65. 14
+0.57
+0.88%
$
13.94B Market Cap
38.79 P/E Ratio
0% Div Yield
2,631,577 Volume
3.91 Eps
$ 64.57
Previous Close
Day Range
64.3 65.4
Year Range
51.9 84.67
Earnings results expected in 47 days
Want to track HOLX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know

Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know

Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks | 10 hours ago
Hologic Climbs 13% in a Month: How Should You Play the Stock?

Hologic Climbs 13% in a Month: How Should You Play the Stock?

After lagging for months, Hologic HOLX has picked up momentum in recent weeks. Shares of the Marlborough, MA-based company have climbed 13.3% over the past month, higher than the industry and the broader Medical sector's gains of 2.4% and 3.4%, respectively.

Zacks | 1 day ago
Hologic Navigates Breast Health Slump: Is the Growth Thesis Intact?

Hologic Navigates Breast Health Slump: Is the Growth Thesis Intact?

HOLX weathers Breast Health softness with rising service revenues, the Endomag acquisition and new tech on the horizon.

Zacks | 6 days ago
Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock

Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock

Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Zacks | 1 week ago
Hologic reportedly rejects $16B go-private offer from TPG, Blackstone

Hologic reportedly rejects $16B go-private offer from TPG, Blackstone

TPG and Blackstone Inc (NYSE:BX), two private equity firms, have made a non-binding offer of more than $16 billion to take medical equipment-maker Hologic Inc (NASDAQ:HOLX) private, according to a media report from the Financial Times. Citing people with knowledge of the matter, the publication said Massachusetts-based Hologic has rejected the offer.

Proactiveinvestors | 2 weeks ago
HOLX vs. DGX: Which Women's Health-Focused Stock Is the Better Pick?

HOLX vs. DGX: Which Women's Health-Focused Stock Is the Better Pick?

With women's health increasingly becoming a global priority, investors are actively targeting companies operating in this space to boost their portfolios. Research and Markets projects the women's health diagnostics market to expand at a compound annual rate of 9.25% through 2030, driven by technological advancements, increasing healthcare expenditures, and initiatives for early detection of women-specific conditions like reproductive health issues, breast cancer, osteoporosis and more.

Zacks | 2 weeks ago
Is Trending Stock Hologic, Inc. (HOLX) a Buy Now?

Is Trending Stock Hologic, Inc. (HOLX) a Buy Now?

Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.

Zacks | 3 weeks ago
Hologic to Webcast Presentations at Upcoming Investor Conferences

Hologic to Webcast Presentations at Upcoming Investor Conferences

MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #holx--Hologic to Webcast Presentations at Upcoming Investor Conferences.

Businesswire | 4 weeks ago
Understanding Hologic (HOLX) Reliance on International Revenue

Understanding Hologic (HOLX) Reliance on International Revenue

Evaluate Hologic's (HOLX) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.

Zacks | 4 weeks ago
Tariffs Dim Hologic's 2025 Expectations: Time to Reassess the Stock?

Tariffs Dim Hologic's 2025 Expectations: Time to Reassess the Stock?

Women's health device maker, Hologic HOLX, slashed its earnings forecast for the full fiscal 2025, even as the latest second-quarter results topped expectations. The revenue target of $4.05-$4.10 billion remained the same as stated during the February earnings call, reflecting the $100 million cut from the initial guidance.

Zacks | 4 weeks ago
Hologic: Soft Performance, But Cheap Enough

Hologic: Soft Performance, But Cheap Enough

Hologic, Inc.'s appeal has increased due to reduced debt, serial buybacks, and modest valuations, despite recent negative organic growth and pricey acquisitions. The company has shown solid long-term growth, reducing leverage significantly and buying back shares, but recent performance has been soft with flattish sales and earnings. Despite a slight cut in earnings guidance and soft organic growth, Hologic's shares now trade at attractive multiples with very manageable leverage.

Seekingalpha | 1 month ago
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know

Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.

Zacks | 1 month ago
Loading...
Load More